Mineralocorticoid receptor antagonism with spironolactone and finerenone has been shown to improve membrane integrity in skeletal and cardiac muscle in murine models of DMD (Hauck et al., 2019; Lowe et al., 2020). Here, NR3C2 is linked to Duchenne muscular dystrophy.